you might use the figures NP stated in the cc (1 w
Post# of 148179
for 2020--1.5 million vials /treats 375 k patients / $ 2.5 billion revenue
they did NOT state if the dosing would change in the s2c as that was to change to IV for 1st dose (Dr. Lalizare)
I believe the $30 million to Samsung is qtrly (about another 5 weeks due again)--this was what NP paid himself last time
the 50% to Vyera while steep was done for cash infusion and not having to ramp up a sales/mkting etc division (CYDY does get cogs returned I believe)